1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N10009
    Cudraflavone B Inhibitor
    Cudraflavone B 是一种异戊二烯化类黄酮,具有抗炎和抗癌特性。Cudraflavone B 也是 COX-1COX-2 的双重抑制剂。Cudraflavone B 阻断巨噬细胞中 核因子 κB (NF-κB) 从细胞质到细胞核的易位。由此,Cudraflavone B 也抑制肿瘤坏死因子 α (TNFα) 的基因表达和分泌。Cudraflavone B 还触发线粒体凋亡通路,激活 NF-κB、MAPK p38ERK,并诱导 SIRT1 的表达。由此,Cudraflavone B 抑制人口腔鳞状细胞癌细胞的生长。
    Cudraflavone B
  • HY-N2195R
    Nootkatone (Standard)

    诺卡酮 (Standard)

    Inhibitor
    Nootkatone (Standard)是 Nootkatone 的分析标准品。本产品用于研究及分析应用。Nootkatone,来自于 Vitis vinifera 的神经保护剂,具有抗氧化和抗炎作用。Nootkatone 可改善脂多糖诱导的阿尔茨海默氏病小鼠模型的认知障碍。
    Nootkatone (Standard)
  • HY-174405
    PROTAC PDE4 degrader-1 Inhibitor
    PROTAC PDE4 degrader-1 (Compound 9m) 是一种具有口服活性的选择性 PDE4 PROTAC降解剂,其 DC50为 41.98 μM。PROTAC PDE4 degrader-1 可有效抑制促炎细胞因子 (例如 TNF-αIL-6) 的分泌。PROTAC PDE4 degrader-1 可显著减轻 LPS (HY-D1056) 诱导的急性肺损伤 (ALI) 小鼠模型中的肺部炎症。粉色:PDE4 ligand (HY-174410);蓝色:CRBN ligase ligand (HY-10984);黑色:linker
    PROTAC PDE4 degrader-1
  • HY-P990270
    Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1)
    Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) 是小鼠来源的、抗小鼠 CD40L/CD154 的 IgG1, κ 抗体抑制剂。
    Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1)
  • HY-N0604R
    Ginsenoside Rh1 (Standard)

    人参皂苷 Rh1 (Standard)

    Inhibitor
    Ginsenoside Rh1 (Standard)是 Ginsenoside Rh1 的分析标准品。本产品用于研究及分析应用。Ginsenoside Rh1 (Prosapogenin A2) 抑制 PPAR-γTNF-αIL-6IL-1β 的表达。
    Ginsenoside Rh1 (Standard)
  • HY-173290
    PDE4D inhibitor 1 Inhibitor
    PDE4-IN-1 是一种 PDE4 抑制剂,具有高效价 (IC50:8.6 nM) 且优于其他 PDE 亚型的选择性。PDE4-IN-1 可抑制炎性细胞因子趋化因子的释放。PDE4-IN-1 可显著修复受损的 cAMP-CREB 信号通路。PDE4-IN-1 可抑制增殖并促进分化,从而逆转银屑病的形成。
    PDE4D inhibitor 1
  • HY-P990249
    Anti-Mouse DR5/CD262 Antibody (MD5-1) Inhibitor
    Anti-Mouse DR5/CD262 Antibody (MD5-1) 是美国仓鼠来源的、抗小鼠 DR5/CD262 的 IgG, κ 抗体抑制剂。
    Anti-Mouse DR5/CD262 Antibody (MD5-1)
  • HY-123568
    PBI-1393 Inhibitor
    PBI-1393 (BCH-1393) 是一种抗癌剂,可增强 Th1 型细胞因子的产生和原发性 T 细胞活化。
    PBI-1393
  • HY-170586
    JAK05 Modulator
    JAK05 对 Helicobacter pylori 具有抑制活性,可抑制 J63、J196 和 J107 菌株,MIC 为 3-5 µg/mL。JAK05 对 H+/K+-ATPaseCOX-1/2TNF-αPGE2 具有结合亲和力,具有抗氧化和抗炎活性。JAK05 在大鼠乙醇诱发的胃溃疡模型中表现出抗溃疡活性。
    JAK05
  • HY-171658
    R1-ICR-5 Inhibitor
    R1-ICR-5 是一种选择性的靶向丝氨酸/苏氨酸蛋白激酶 1 (RIPK1) PROTAC 降解剂。R1-ICR-5 通过 VHL 介导,促使 RIPK1 发生降解,进而失调 TNFR1 和 TLR3/4 信号枢纽,增强 NF-κB、MAPK 和 IFN 信号输出,同时促进 RIPK3 激活和坏死性凋亡的诱导。R1-ICR-5 有望用于癌症和炎症性疾病的研究。(粉色:PK68 (HY-128348);黑色:linker (HY-W012241);蓝色:(S,R,S)-AHPC (HY-125845)。
    R1-ICR-5
  • HY-N0616R
    Trifolirhizin (Standard)

    三叶豆紫檀苷 (Standard)

    Trifolirhizin (Standard) 是 Trifolirhizin 的分析标准品。本产品用于研究及分析应用。Trifolirhizin 是从苦参根中分离出的一种 pterocarpan 黄酮类化合物。Trifolirhizin 具有高效的 tyrosinase 抑制活性,IC50 为 506 μM。Trifolirhizin 具有潜在的抗炎和抗癌活性。
    Trifolirhizin (Standard)
  • HY-P990809
    Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3)
    Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) 是大鼠来源的 IgG1 kappa 小鼠来源的抗体,靶向 4-1BB/CD137。Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) 的同型对照为 Rat IgG1 kappa, Isotype Control (HY-P99979)。
    Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3)
  • HY-153690
    Progranulin modulator-1 Inhibitor
    Progranulin modulator-1是一种口服有效的前颗粒蛋白 (progranulin,PGRN) 分泌增强剂。Progranulin modulator-1增强对BV-2效力来提高PGRN水平的且对hERG有抑制作用,细胞毒性低,对 PGRN 的 EC50 和 hERG 的 IC50 分别为 83,3100 nM。
    Progranulin modulator-1
  • HY-161381
    PDE4-IN-15 Inhibitor
    PDE4-IN-15 (compound 7b-1) 是 PDE4 的抑制剂 (IC50 = 0.17 μM),具有抗 TNF-α 活性 (EC50 = 0.19 μM)。PDE4-IN-15 具有良好的皮肤渗透性。
    PDE4-IN-15
  • HY-144727
    Anti-inflammatory agent 11 Inhibitor
    Anti-inflammatory agent 11 (化合物 16) 是一种有效的抗结核分枝杆菌和抗炎剂。Anti-inflammatory agent 11 抑制 Mtb H37RvM299 生长,其 MIC50 (最低抑制浓度 50%) 分别为 1.3 和 6.9 μM。Anti-inflammatory agent 11 通过抑制 iNOS 表达抑制 NO,同时抑制 TNF-α 和 IL-1β 的产生。Anti-inflammatory agent 11 可用于结核病的研究。
    Anti-inflammatory agent 11
  • HY-126232
    Verproside Inhibitor
    Verproside,一种从 Pseudolysimachion 属分离的梓醇衍生物环烯醚萜苷,通过 IKK/IκB 信号级联反应抑制 NF-κB 活化,抑制TNF-α 诱导的 MUC5AC 表达。Verproside具有有效的抗炎,抗氧化,抗伤害和抗哮喘作用,并且可用于慢性阻塞性肺疾病 (COPD) 的研究。
    Verproside
  • HY-163035
    EM-163 Inhibitor
    EM-163 是一种合成的 BB-Loop 模拟物。EM-163 可以通过靶向 MyD88 的 TIR 结构域,缓解炎症并防止中毒性休克导致的死亡。EM-163 可以用于 SEB 中毒的研究 (SEB: 葡萄球菌肠毒素 B)。
    EM-163
  • HY-120794
    SC-67655
    SC 67655 是一种强效且稳定的五肽 MHC II 类单倍型 DR4(DR4 Dw4 或 DRB 1"0401)配体,IC50 为 50 nM。SC 67655 可用于自身免疫性疾病的研究。
    SC-67655
  • HY-P990528
    Anti-TNFRSF7/CD27 Antibody Inhibitor
    Anti-TNFRSF7/CD27 Antibody 是 CHO 表达的人源抗体,靶向 TNFRSF7/CD27。Anti-TNFRSF7/CD27 Antibody 带有 huIgG2 型重链和 huκ 型轻链,其预测的分子量 (MW) 为 145 kDa。Anti-TNFRSF7/CD27 Antibody 的同型对照可参考 Human IgG2 kappa, Isotype Control (HY-P99002)。
    Anti-TNFRSF7/CD27 Antibody
  • HY-149816
    Anti-inflammatory agent 41 Inhibitor
    Anti-inflammatory agent 41 (13a) 显著抑制脂多糖(LPS)诱导的J774A.1、THP-1和LX-2细胞中促炎细胞因子IL-6和TNF-α的表达,并抑制了NF-κB通路的激活。
    Anti-inflammatory agent 41
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.